Key Highlights
- Venture Life Group Plc (LSE:VLG) shares rose 4.58% on 1 October 2026.
- Final results for the 17 months to 31 May 2026 showed continuing Revenue of £50.0 million.
- Underlying growth was 16.0% on a proforma basis, driven by 14.8% Volume growth.
- Online revenue rose to £12.8 million, or 25.6% of group revenue.
- The company announced a CEO succession and held an investor presentation on 1 October.
Why Venture Life Is in Focus Today
Venture Life Group Plc (LSE:VLG), the consumer healthcare company focused on product innovation and commercialisation, gained 4.58% on 1 October 2026. The move came two days after the company published its final results and announced a chief executive succession, and on the same day management presented the results to investors at a live online presentation.
The rise contrasted with a weak wider market, as the FTSE 100 dropped more than 1%. Ahead of the results, the shares had been trading around 67.5 pence, close to their 12-month high of 72 pence and well above an early-May low of about 54 pence.
Strong Underlying Growth
Venture Life changed its financial year end from December to May, so its latest audited results cover a 17-month period to 31 May 2026. Group revenue from continuing operations reached £50.0 million, compared with £26.6 million for the 2024 calendar year. On a like-for-like proforma basis, comparing with the previous 17 months to May 2025, underlying growth was 16.0%.
Crucially, that growth was driven mostly by volume rather than price, with 14.8% from volume and 1.2% from pricing. Volume-led growth is generally viewed as higher quality, because it reflects genuine Demand for products rather than inflation.
Innovation and Distribution Gains
The company launched 19 new products during the period, and newly launched products contributed 9.4% of group revenue, up from 6.1% in 2024. Distribution points rose by about 40%, meaning its brands are available in significantly more retail locations.
Online revenue more than doubled to £12.8 million from £5.0 million, representing 25.6% of group revenue. Direct-to-consumer and marketplace channels typically offer better margins and richer customer data, supporting future growth.
Health and Her Becoming a Power Brand
A central part of the Venture Life story is Health and Her, acquired in November 2024. The Brand has become the number one menopause supplement brand in the UK by value sales and has expanded into the US, including listings in around 6,000 CVS stores and on Walmart Marketplace. Menopause and healthy longevity are fast-growing categories, and Health and Her gives Venture Life a strong position in them.
Transformation Costs Weigh on Reported Profit
The period included significant transformation activity. Venture Life sold its contract development and Manufacturing operations in 2025 to become a capital-light, brand-focused business, and it invested in a group-wide ERP platform, with £3.1 million of related costs classed as exceptional. As a result, the total group reported an operating loss of about £9.6 million on a statutory basis, compared with an operating profit in the prior period.
Investors appear to be looking through these one-off costs to the underlying trading, which is why the shares responded positively.
CEO Succession in Focus
Alongside the results, Venture Life announced a CEO succession plan. Chief executive Jerry Randall has led the group through its transformation and presented the results to investors on 1 October, and the transition process is now a key focus for shareholders. Management changes can unsettle smaller companies, but a planned succession after a strategic reset tends to be viewed more calmly by the market.
Institutional interest also remains visible, with asset manager Liontrust disclosing a holding of just under 4.91% in late September.
What to Watch Next
The next update for Venture Life Group Plc (LSE:VLG) will be interim financial statements for the six months to 30 September 2026, expected in November. Investors will want to see continued volume growth, Margin expansion now that transformation costs are behind the business, progress on US expansion for Health and Her, and further detail on the Leadership transition.






Please wait processing your request...